Ott CJ, Wu CJ. HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL. Cancer Cell. 2017;32(1):1-3. doi:10.1016/j.ccell.2017.06.008
Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc. 2003;125(19):5586-7. doi:10.1021/ja0341440
Hassig CA, Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol. 1997;1(3):300-8.
Porter NJ, Wagner FF, Christianson DW. Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6. Biochemistry. 2018;57(26):3916-3924. doi:10.1021/acs.biochem.8b00367
Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A. 2003;100(8):4389-94. doi:10.1073/pnas.0430973100
Fass DM, Reis SA, Ghosh B, et al. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology. 2013;64:81-96. doi:10.1016/j.neuropharm.2012.06.043
Dirice E, Ng RWS, Martinez R, et al. Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes. J Biol Chem. 2017;292(43):17598-17608. doi:10.1074/jbc.M117.804328
Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002;9(1):3-16.
Kemp MM, Wang Q, Fuller JH, et al. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorg Med Chem Lett. 2011;21(14):4164-9. doi:10.1016/j.bmcl.2011.05.098
Verma MS, Fink MJ, Salmon GL, et al. A Common Mechanism Links Activities of Butyrate in the Colon. ACS Chem Biol. 2018;13(5):1291-1298. doi:10.1021/acschembio.8b00073